Globus Medical chair granted 100,000 stock options

Globus Medical Inc. reported that Executive Chairman and director Paul David C, who is also a 10% owner, received a grant of stock options.

Rhea-AI Filing Summary

Globus Medical Inc. reported that Executive Chairman and director Paul David C, who is also a 10% owner, received a grant of stock options. On January 21, 2026, he was awarded 100,000 stock options to buy Class A common stock at an exercise price of $94.15 per share, with the options themselves granted at a cost of $0.

The options vest over four years, with one quarter vesting on January 1, 2027 and the remaining three quarters vesting in equal monthly installments over the following three years. After this grant, he beneficially owns 100,000 derivative securities directly in the form of these options.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider Paul David C

Role Executive Chairman

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy Class A Common Stock)	100,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy Class A Common Stock) — 100,000 contracts (Direct)

Footnotes (1)

1. F1. These options were granted on January 21, 2026, and vest over a four-year period with 1/4 of the options vesting on January 1, 2027, then 1/48 of the options vesting each month thereafter.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Globus Medical (GMED) disclose in this Form 4?

The filing shows that Executive Chairman and director Paul David C was granted 100,000 stock options to buy Globus Medical Class A common stock.

What is the exercise price of the options granted to Paul David C at Globus Medical (GMED)?

The stock options have an exercise price of $94.15 per share for Globus Medical Class A common stock.

How do the new stock options for Globus Medical (GMED) Executive Chairman vest?

The options vest over four years: 1/4 vests on January 1, 2027, and the remaining 3/4 vests in 1/48 monthly installments thereafter.

How many derivative securities does the Globus Medical (GMED) insider own after this Form 4 transaction?

After the grant, 100,000 derivative securities (stock options) are beneficially owned directly by the reporting person.

What roles does the reporting person hold at Globus Medical (GMED)?

The reporting person is an Executive Chairman, a director, and a 10% owner of Globus Medical Inc.

Was there any purchase price paid for the Globus Medical (GMED) options themselves?

The options were reported with a price of $0 for the derivative security, meaning no cash price was shown for receiving the grant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/23/2026 - 05:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Paul David C

(Last) (First) (Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVENUE

(Street)

AUDUBON PA 19403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)	$94.15	01/21/2026		A		100,000		(1)	01/21/2036	Class A Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. These options were granted on January 21, 2026, and vest over a four-year period with 1/4 of the options vesting on January 1, 2027, then 1/48 of the options vesting each month thereafter.

	/s/ Kelly G. Huller, Attorney-in-Fact	01/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.